MX2022009677A - Composiciones para el tratamiento de enfermedades oculares. - Google Patents
Composiciones para el tratamiento de enfermedades oculares.Info
- Publication number
- MX2022009677A MX2022009677A MX2022009677A MX2022009677A MX2022009677A MX 2022009677 A MX2022009677 A MX 2022009677A MX 2022009677 A MX2022009677 A MX 2022009677A MX 2022009677 A MX2022009677 A MX 2022009677A MX 2022009677 A MX2022009677 A MX 2022009677A
- Authority
- MX
- Mexico
- Prior art keywords
- ocular diseases
- edonentan
- agent
- compositions
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971002P | 2020-02-06 | 2020-02-06 | |
| US202063010212P | 2020-04-15 | 2020-04-15 | |
| PCT/US2021/016414 WO2021158663A1 (en) | 2020-02-06 | 2021-02-03 | Compositions for treatment of ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009677A true MX2022009677A (es) | 2022-09-09 |
Family
ID=77200537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009677A MX2022009677A (es) | 2020-02-06 | 2021-02-03 | Composiciones para el tratamiento de enfermedades oculares. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11873279B2 (https=) |
| EP (1) | EP4100406A4 (https=) |
| JP (2) | JP2023512763A (https=) |
| KR (1) | KR20220143685A (https=) |
| CN (1) | CN115103842A (https=) |
| AU (1) | AU2021217358A1 (https=) |
| BR (1) | BR112022015579A2 (https=) |
| CA (1) | CA3168810A1 (https=) |
| IL (1) | IL294873A (https=) |
| MX (1) | MX2022009677A (https=) |
| WO (1) | WO2021158663A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4050997A4 (en) * | 2019-10-30 | 2022-11-30 | Perfuse Therapeutics, Inc. | TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS |
| CA3168810A1 (en) | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
| CA3218398A1 (en) * | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
| EP4329753A4 (en) | 2021-04-30 | 2025-02-26 | Perfuse Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES |
| WO2025137005A1 (en) * | 2023-12-20 | 2025-06-26 | Perfuse Therapeutics, Inc. | Methods of preparing drug delivery systems for the treatment of ocular diseases |
| WO2025137007A1 (en) * | 2023-12-20 | 2025-06-26 | Perfuse Therapeutics, Inc. | Methods of preparing drug delivery systems for the treatment of ocular diseases |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4282793A (en) | 1992-04-10 | 1993-11-18 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | A microneedle for injection of ocular blood vessels |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| JP2004525890A (ja) | 2001-02-02 | 2004-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤 |
| US20030176356A1 (en) * | 2001-04-24 | 2003-09-18 | University Of North Texas Health Science Center | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| BRPI1013904A2 (pt) | 2009-04-30 | 2016-07-19 | Univ Midwestern | método e composição para tratar cetoacidose diabética |
| US20110082151A1 (en) | 2009-06-12 | 2011-04-07 | Auspex Pharmaceuticals, Inc. | Sulfonylurea modulators of endothelin receptor |
| KR20130050939A (ko) | 2010-04-12 | 2013-05-16 | 가부시키가이샤 아루떼꾸 우에노 | 망막 질환의 치료 방법 및 이를 위한 안과용 조성물 |
| MX390909B (es) | 2013-12-19 | 2025-03-21 | Tassos Georgiou | Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso. |
| MX2016009331A (es) * | 2014-01-23 | 2016-10-26 | Akebia Therapeutics Inc | Composiciones y metodos para tratar enfermedades oculares. |
| ES2584534B1 (es) * | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| CN107921036A (zh) | 2015-05-29 | 2018-04-17 | 优势医疗公司 | 用于减少视力丧失的组合物和方法 |
| JP6745594B2 (ja) * | 2015-11-26 | 2020-08-26 | 持田製薬株式会社 | ピラゾール誘導体の塩の結晶 |
| WO2017217967A1 (en) | 2016-06-13 | 2017-12-21 | Noveome Biotherapeutics, Inc. | Novel methods for delivering therapeutic agents to the eye via nasal passages |
| WO2018185516A1 (en) * | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| EP3642214A2 (en) | 2017-06-19 | 2020-04-29 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| JP2020528082A (ja) | 2017-07-17 | 2020-09-17 | ロイズマン，キース | 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達 |
| JP7134983B2 (ja) * | 2017-09-15 | 2022-09-12 | 持田製薬株式会社 | テトラヒドロナフチルウレア誘導体の結晶 |
| WO2019210194A1 (en) | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| EP4050997A4 (en) | 2019-10-30 | 2022-11-30 | Perfuse Therapeutics, Inc. | TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS |
| CA3168810A1 (en) | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
-
2021
- 2021-02-03 CA CA3168810A patent/CA3168810A1/en active Pending
- 2021-02-03 WO PCT/US2021/016414 patent/WO2021158663A1/en not_active Ceased
- 2021-02-03 MX MX2022009677A patent/MX2022009677A/es unknown
- 2021-02-03 KR KR1020227030697A patent/KR20220143685A/ko active Pending
- 2021-02-03 AU AU2021217358A patent/AU2021217358A1/en active Pending
- 2021-02-03 BR BR112022015579A patent/BR112022015579A2/pt unknown
- 2021-02-03 IL IL294873A patent/IL294873A/en unknown
- 2021-02-03 CN CN202180013043.1A patent/CN115103842A/zh active Pending
- 2021-02-03 EP EP21751181.5A patent/EP4100406A4/en active Pending
- 2021-02-03 JP JP2022547697A patent/JP2023512763A/ja active Pending
-
2022
- 2022-08-02 US US17/879,627 patent/US11873279B2/en active Active
-
2023
- 2023-12-04 US US18/528,378 patent/US20240109876A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093285A patent/JP2025120268A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115103842A (zh) | 2022-09-23 |
| US11873279B2 (en) | 2024-01-16 |
| WO2021158663A1 (en) | 2021-08-12 |
| JP2023512763A (ja) | 2023-03-29 |
| JP2025120268A (ja) | 2025-08-15 |
| US20240109876A1 (en) | 2024-04-04 |
| EP4100406A1 (en) | 2022-12-14 |
| BR112022015579A2 (pt) | 2022-10-11 |
| EP4100406A4 (en) | 2023-07-05 |
| US20230120974A1 (en) | 2023-04-20 |
| CA3168810A1 (en) | 2021-08-12 |
| KR20220143685A (ko) | 2022-10-25 |
| IL294873A (en) | 2022-09-01 |
| AU2021217358A1 (en) | 2022-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009677A (es) | Composiciones para el tratamiento de enfermedades oculares. | |
| Kennedy et al. | Selective laser trabeculoplasty: an update | |
| NZ588938A (en) | Sustained release delivery of active agents to treat glaucoma and ocular hypertension | |
| MX2022005063A (es) | Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina. | |
| TW200633709A (en) | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | |
| EP4397375A3 (en) | Isoxazoline parasiticide formulations and methods for treating blepharitis | |
| TW200621236A (en) | Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases | |
| CA3167959A1 (en) | Prodrug for the treatment of disease and injury of oxidative stress | |
| MX2022001069A (es) | Composiciones y metodos para el tratamiento de la presbicia. | |
| EA202192183A1 (ru) | Композиции, обладающие активностью удаления липофусцина из клеток сетчатки | |
| BR112022025908A2 (pt) | Formulações à base de ácido hialurônico para tratamento e prevenção de hipertensão ocular e glaucoma | |
| WO2021220061A3 (en) | Heterodimer compositions and methods for the treatment of ocular disorders | |
| EA201690903A1 (ru) | Лечение глаукомы с использованием лаквинимода | |
| JP6653898B1 (ja) | 非侵襲的角膜又は強膜強化装置 | |
| MY205498A (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| CL2024003281A1 (es) | Anticuerpos específicos contra la proteína 7 relacionada con la angiopoyetina y usos de estos | |
| WO2023192828A3 (en) | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases | |
| WO2023212707A3 (en) | Therapeutic modulation of genes in myeloid lineage cells and uses thereof in ophthalmology | |
| EP4559529A3 (en) | Isocyclosporin a for topical treatment of ocular diseases | |
| WO2024211322A3 (en) | Ripasudil based ophthalmic treatments | |
| CR20230190A (es) | Compuesto degradante en un medicamento | |
| MX2023001950A (es) | Compuestos y formulaciones para el tratamiento de enfermedades oftalmicas. | |
| WO2023283554A3 (en) | Compositsons and methods for decreasing pigmentation | |
| Štěpánková et al. | Simultaneous bilateral acute angle-closure glaucoma in miller fisher syndrome | |
| WO2007025275A3 (en) | Control of induced elevated intraocular pressure |